28 search results for Pancreatic Adenocarcinoma
Specific Populations
: 2024 Pancreatic Cancer Version: 2023, : 2024 Small Bowel Adenocarcinoma Version, Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/specific-populationsNCCN-2025-Annual-Conference-Exhibit-Guide
• Gastrointestinal Stromal Tumors (GIST) • Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, -Small Cell Lung Cancer: Metastatic • Ovarian Cancer • Palliative Care • Pancreatic Cancer, Bowel Adenocarcinoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Squamous Cell Skin Cancer
https://www.nccn.org/docs/default-source/education-research/nccn-2025-annual-conference-exhibit-guide.pdf?sfvrsn=5765e4e8_5ORP Grant History
with Advanced Pancreatic Cancer Renuka Iyer, MD Roswell Park Comprehensive Cancer Center Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer, Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic and Biliary Carcinomas Daniel Laheru, ) Genotype-Directed Phase II Trial of Oral Capecitabine for 2nd Line Treatment of Advanced Pancreatic Cancer, Adenocarcinoma Lakshmi Pendyala, PhD Roswell Park Comprehensive Cancer Center Gene Expression
https://www.nccn.org/education-research/nccn-oncology-research-program/orp-grant-historyGuidelines With Evidence Blocks
Pancreatic Adenocarcinoma Version 2.2025 Pediatric Acute Lymphoblastic Leukemia, Leukemia Version 3.2024 Acute Myeloid Leukemia Version 2.2025 Ampullary Adenocarcinoma, Adenocarcinoma Version 2.2025 Small Cell Lung Cancer Version 4.2025 Soft Tissue Sarcoma
https://www.nccn.org/guidelines/guidelines-with-evidence-blocksFramework for Resource Stratification
Framework Version 4.2024 NCCN Guidelines Version 3.2025 Pancreatic Adenocarcinoma
https://www.nccn.org/global/what-we-do/nccn-framework-for-resource-stratification-of-nccn-guidelinesChemotherapy Order Templates Reviewer Acknowledgement
Pancreatic Adenocarcinoma Sally Barbour, PharmD, BCOP, FHOPA, CPP, of Medicine Ampullary Adenocarcinoma Jennah Bauernfeind, Hospital and Solove Research Institute Small Bowel Adenocarcinoma
https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagementAnnual Report
Polymerase as Maintenance Treatment for Advanced TP53 Mutant Pancreatic Ductal Adenocarcinoma Chengwei, Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
https://www.nccn.org/docs/default-source/about/annual-report.pdf?sfvrsn=8411082_40Submission Request History
Adenocarcinoma Submitted by Merck & Co., Inc. on 06/17/2020 Tumor Mutational Burden (TMB) for Colon, on 09/08/2020 Tumor Mutational Burden (TMB) for Small Bowel Adenocarcinoma Submitted, Dostarlimab-gxly for Small Bowel Adenocarcinoma Submitted by GlaxoSmithKline on 08/17/2021, Adenocarcinoma Submitted by Bristol-Myers Squibb Company on 04/11/2022 Nivolumab + ipilimumab, Selpercatinib for Small Bowel Adenocarcinoma Submitted by Eli Lilly and Company on 09/21/2022
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-history